Issues at Suez Canal Delay Containers from India
Non-GMO soybean prices are not experiencing a robust move in their premiums. The premium over the conventional local prices...
Blog
Ongoing Quest for FDA Guidance
CBD policy development at the FDA has by all appearances, been set aside. The cannabinoid segment sees regulatory guidance as paramount to grow markets. CPG heavyweights have been sidelined by the regulatory vacuum, and the fact that some states are legislating for CBD doesn’t appear to inspire them. New York’s unfolding
